Gilead to build manufacturing site in Maryland to boost cell therapy

The new facility should help the big biotech meet some of the unique challenges of manufacturing CAR-T therapies. The process is complex and time...

Bayer backs cell therapy startup with $215M in funding

First-generation cell therapies, such as those developed by Novartis and Gilead, rely on immune cells collected from each individual patient. A painstaking manufacturing process then...

Biotechs dive deeper into targeted cancer research, despite costs

"It could become very challenging for a small biotech company, or even a pharma company, to cover that part of a clinical trial test," said...

BioNTech buys MAB Discovery’s antibody research unit

Known for its work in the field of messenger RNA therapeutics, BioNTech is looking for new ways to grow. Earlier this month, the private...
"It could become very challenging for a small biotech company, or even a pharma company, to cover that part of a clinical trial test,"...
Authorities warn that antibiotic-resistant infections rank high, if not at the top, of public and global health concerns. TB offers a prime...
CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)...

Follow RXMonthly

News

R&D leaders worry pharma reputation risks losing talent

PHILADELPHIA — It's not artificial intelligence or creative corporate structures that some of the biopharma industry's leaders see as the best way to boost...

Sangamo backs up early success for hemophilia gene therapy

In gene therapy, where dramatic results in deadly diseases can hasten clinical testing, studies tend to be smaller, with greater significance put on each...

In a first, pharma distributor and execs face criminal...

The RDC prosecution could serve as a warning to the drug distribution industry, potentially impacting litigation against the three largest players: McKesson, AmerisourceBergen and...

Pfizer muscular dystrophy gene therapy stumbles on safety

Dive Brief: Pfizer's Duchenne muscular dystrophy gene therapy improved physical function in two patients measured one year after treatment, but also led to one patient...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter